TAK-243
A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1
- Enrollment
- 42 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Ubiquitin-Activating Enzyme Inhibitor (UBA1)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2066
- NCT Identifier
- NCT03816319
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.